Literature DB >> 15389998

Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report.

Giovanni Cossu1, Maurizio Melis, Giannina Melis, Elisabetta Maccioni, Valeria Putzu, Olga Catte, Paolo Francesco Putzu.   

Abstract

We report on a case of reversible Pisa syndrome developed after treatment with galantamine in a patient with Alzheimer's disease without previous exposure to neuroleptic or other cholinesterase inhibitors. Complete and persistent resolution of the syndrome was achieved several weeks after botulinum toxin type-A injection. (c) 2004 Movement Disorder Society.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15389998     DOI： 10.1002/mds.20164

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  6 in total

1.  Lateral trunk flexion in Parkinson's disease: EMG features disclose two different underlying pathophysiological mechanisms.

Authors:  Alessandro Di Matteo; Alfonso Fasano; Giovanna Squintani; Lucia Ricciardi; Tommaso Bovi; Antonio Fiaschi; Paolo Barone; Michele Tinazzi
Journal:  J Neurol       Date:  2010-11-16       Impact factor: 4.849

2.  Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease.

Authors:  Andrea Santamato; Maurizio Ranieri; Francesco Panza; Stefano Zoccolella; Vincenza Frisardi; Vincenzo Solfrizzi; Maria Teresa Amoruso; Loredana Amoruso; Pietro Fiore
Journal:  J Neurol       Date:  2010-01       Impact factor: 4.849

3.  Pisa syndrome as presenting symptom of amyotrophic lateral sclerosis.

Authors:  Marcello Deriu; Daniela Murgia; Alessandra Paribello; Emanuele Marcia; Maurizio Melis; Giovanni Cossu
Journal:  J Neurol       Date:  2011-04-23       Impact factor: 4.849

Review 4.  Hyperkinetic Movement Disorder Emergencies.

Authors:  Giovanni Cossu; Carlo Colosimo
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

5.  Pisa syndrome induced by switching of a choline-esterase inhibitor treatment from donepezil to galantamine: a case report.

Authors:  Yu Mimura; Shin Kurose; Taketo Takata; Hajime Tabuchi; Masaru Mimura; Michitaka Funayama
Journal:  BMC Neurol       Date:  2020-05-13       Impact factor: 2.474

6.  A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors.

Authors:  Maria Cristina B Diaz; Raymond L Rosales
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.